Trial Profile
The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Therapeutic Use
- Acronyms CAD5
- 06 Jan 2017 Status changed from recruiting to completed.
- 27 Feb 2016 New trial record